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Abstract: Genetically diabetic Akita mice, kept on a high-fat and high-cholesterol diet, and treated with the peroxisome prolifera-
tor-activated receptor-c agonist rosiglitazone (10 mg/kg per day during 4 months), displayed rosiglitazone-induced side effects,
similar to those observed in patients, including weight and fat gain and early signs of hypertrophic cardiomyopathy. As several
cases of hepatotoxicity were reported in patients receiving rosiglitazone treatment, this study evaluated whether rosiglitazone also
induced hepatotoxicity in these diabetic animals. Liver structure and function was analysed in wild-type and rosiglitazone-treated
and untreated Akita mice, kept for 4 months on the high-fat and high-cholesterol diet. Decreased circulating levels of the liver
enzymes aspartate and alanine aminotransferase and increased levels of alkaline phosphatases were observed upon rosiglitazone
treatment, whereas liver weight was markedly increased. Rosiglitazone administration was associated with liver steatosis, as dem-
onstrated by triglyceride accumulation. However, gene expression of steatosis markers in liver tissue was not markedly affected
by rosiglitazone treatment, while expression of fatty acid transport protein was reduced by rosiglitazone treatment, suggesting an
impairment of the fatty acid b-oxidation pathway. mRNA expression of pro- and anti-oxidant enzymes and liver 3-nitrotyrosine
content was not affected. Furthermore, gene and protein expression of macrophage markers and of cell adhesion molecules did
not indicate progression to steatohepatitis, whereas an unaltered collagen deposition did not suggest steatofibrosis. In conclusion,
rosiglitazone treatment of diabetic Akita mice induced liver steatosis without, however, progression to more advanced stages of
liver disease.
Insulin resistance is an important cause of non-alcoholic fatty
liver disease, one of the most common forms of chronic liver
disease [1–5]. Thiazolidinediones, including rosiglitazone, are
peroxisome proliferator-activated receptor-c (PPAR-c) agonists
that improve diabetes by increasing tissue sensitivity for insu-
lin [6]. However, large-scale clinical use has revealed serious
side effects such as water retention, cardiovascular toxicity
and weight gain [7]. The molecular mechanisms underlying
these complications are poorly understood, to some extent due
to the lack of suitable diabetic animal models. Pre-clinical
models in rodents indeed appeared to have only limited pre-
dictive power in respect to the observed clinical adverse
effects associated with rosiglitazone [8]. Next to drug-induced
cardiac toxicity, drug-induced liver injury is the second largest
cause for the withdrawal of drugs from the market or for stop-
ping the drug development process in its early-phase, thus
causing huge financial losses [9]. The mechanisms of drug-
induced liver injury are not fully clear, especially the mecha-
nism by which rosiglitazone caused liver toxicity [10,11].
Common manifestations of drug-induced liver injury include
lipid storage disorders, such as steatosis or phospholipidosis.
Drug-induced steatosis, characterized by an increased accumu-
lation of lipids in the form of triglycerides, is a serious issue
for pharmaceutical companies as it could lead to liver failure,
resulting in the withdrawal of the drug from the market
[12,13]. In this study, we have used the Ins2Akita mouse to
evaluate the hepatotoxic effect of rosiglitazone. The Akita
mice have a spontaneous point mutation (Cys96 to Tyr) in the
insulin 2 gene, leading to accumulation of misfolded pro-insu-
lin in the endoplasmatic reticulum and eventually to apoptosis
of b-cells and failure to secrete mature insulin [14,15]. These
mice develop hyperglycaemia, hypoinsulinaemia, polydipsia
and polyuria and are frequently used to study complications
associated with type 1 diabetes. They also develop type 2 dia-
betes with insulin resistance in skeletal muscle, liver and
brown adipose tissue that is partly due to hyperglycaemia
[14,15]. Therefore, the Akita mouse is frequently used as a
model for both type 1 and type 2 diabetes. In a previous
study, rosiglitazone administration to Akita mice fed a high-fat
and high-cholesterol diet for 4 months, showed body-weight
and fat mass gain and early signs of hypertrophic cardiomyop-
athy [16]. As liver disease is associated with insulin resistance,
and hepatotoxicity and liver failure are potential side effects of
rosiglitazone treatment, we have studied the potential mecha-
nisms of rosiglitazone in different stages of non-alcoholic fatty
liver disease in the genetically diabetic Akita mouse.
Materials and Methods
Animal model. Male Akita mice (C57Bl/6J genetic background) were
purchased from The Jackson Laboratories (Bar Harbor, MN, USA).
Mice were kept in individual micro-isolation cages on a 12-hr day/
night cycle at 20–22°C and exposed ad libitum to water and regular
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chow. From 10-week-old mice, plasma was prepared after an
overnight fasting by collecting blood from the retro-orbital sinus on
3.8% trisodium citrate. The animals were then put on a high-fat and
high-cholesterol diet (19.5% fat and 1.25% cholesterol; E15751-30,
Sniff Spezialit€aten GmbH, Soest, Germany) for 4 months. Male wild-
type C57Bl/6J mice (n = 6) were also kept on the high-fat and high-
cholesterol diet for comparison. Akita mice were divided into two
groups (n = 6 each): one group received the high-fat and high-
cholesterol diet with rosiglitazone (10 mg/kg body-weight per day),
while the control group received only the high-fat and high-cholesterol
diet. Rosiglitazone was custom made by Apin Chemicals Limited
(Oxon, UK). This dosage regimen of rosiglitazone was based on
previous experiments in rodents [16,17]. After 4 months, plasma was
collected and the mice were killed with an i.p. injection of 60 mg/kg
sodium pentobarbital (Nembutal, Abbott Laboratories, North Chicago,
IL, USA). After a saline perfusion step to remove blood from all
organs, the washed liver was removed, weighed and divided in
portions for histological analysis, RNA extraction and biochemical
analyses. All the animal procedures were approved by the Ethical
Committee of the KU Leuven and performed in accordance with the
NIH Guide for the Care and Use of Laboratory Animals (1996).
Histology and immunohistochemistry. Liver tissue was fixed with 1%
paraformaldehyde in phosphate-buffered saline for 20 hr at 4°C,
paraffin-embedded and prepared as cross sections of 8 lm. Liver
sections were stained with haematoxylin and eosin (H&E) and with
Sirius Red (SR) as described previously [18]. Liver sections were also
deparaffinized, rehydrated and used for immunohistochemical
detection of 3-nitrotyrosine (3-NT), F4/80, Mac-3, intercellular
adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1
(VCAM-1) and cytokeratin-19 (CK-19) antigen. Antigens for the 3-
NT, F4/80 and Mac-3 stainings were exposed by incubating sections
with an antigen retrieval solution (DAKO, Heverlee, Belgium)
according to the manufacturer’s instructions. To expose CK-19
antigens, liver sections were incubated for 7 min. with trypsin (25 lg/
ml in 0.1% CaCl2). All sections were then incubated for 20 min. with
methanol supplemented with 0.3% H2O2 at room temperature to block
endogenous peroxidase activity. A specific binding to secondary
antibodies (Abs) was prevented by incubating sections with 20% pre-
immune rabbit serum (45 min., room temperature, X0902, DAKO) for
the F4/80, Mac-3, ICAM-1 and VCAM-1 stainings or with 20% or
5% pre-immune goat serum (45 min., room temperature, X0907,
DAKO) for the 3-NT and CK-19 staining, respectively. Primary and
secondary Abs were diluted in Tris-NaCl-blocking buffer and
incubated at room temperature: primary Abs were rabbit anti-
nitrotyrosine (1/1000, 1 hr, 06-284, Millipore, 25 Billerica, MA,
USA), rat anti-mouse F4/80 (1/100, overnight (ON), MCAP497, AbD
Serotec, D€usseldorf, Germany), rat anti-mouse Mac-3 (1/50, ON,
553322, Pharmingen, San Diego, CA, USA), goat anti-mouse ICAM-1
(1/250, ON, AF796, R&D Systems, Minneapolis, MN, USA), goat
anti-mouse VCAM-1 (1/100, ON, AF643, R&D Systems) or rabbit
anti-mouse CK-19 (1/100, ON, ab15463, Abcam, Cambridge, UK)
followed by secondary Abs horseradish peroxidase (HRP)-labelled
goat anti-rabbit (GAR) Ab (1/100, 45 min., P0448, DAKO) for the 3-
NT staining, biotinylated (B) rabbit anti-rat antibody (1/300, 45 min.,
E0468, DAKO) pre-incubated with 10% pre-immune mouse serum
(M5905, Sigma-Aldrich, St. Louis, MO, USA) for F4/80 and Mac-3
antigen visualization, rabbit anti-goat-B antibody (1/300, 45 min.,
E0466, DAKO) preincubated with 10% pre-immune mouse serum for
the ICAM-1 and VCAM-1 stainings, and GAR-B antibody (1/300,
45 min., E0432, DAKO) for the CK-19 staining. For signal
amplification, the Tyramide Signal Amplification Cyanine 3 System
(Perkin Elmer, Boston, MA, USA) (F4/80, Mac-3, CK-19) or
streptavidin-HRP (Perkin Elmer) in Tris-NaCl-blocking buffer (1/100,
30 min., room temperature) (ICAM-1, VCAM-1) was used. For the
3-NT, ICAM-1, VCAM-1 and CK-19 stainings 3, 3-diaminobenzidine
were applied for detection with Harris counterstaining (ICAM-1,
VCAM-1). Sections were dehydrated and mounted with dibutyl
phthalate xylene (3-NT, ICAM-1, VCAM-1, CK-19) or mounted with
Prolong Gold with 4’,6-diamidino-2-phenylindole (DAPI, Life
Technologies, Carlsbad, CA, USA) (F4/80) or Vectorshield with
DAPI (Vector Laboratories, Inc., Burlingame, CA, USA) (Mac-3).
Microscopy analysis. H&E, SR, Mac-3, 3-NT, ICAM-1 and VCAM-1
stainings were analysed with a Zeiss AxioVert 200M microscope
(Zeiss, Jena, Germany), while images of F4/80-stained liver sections
were taken using an AxioPlan 2 Imaging microscope (Zeiss). Pictures
were taken at random (minimal 4 images per liver section, 2-4
sections per liver) and analysed through computer-assisted image
analysis (AxioVision Rel 4.8, Zeiss) at 400 9 magnification. The
amount of macrophages (F4/80, Mac-3), adhesion molecules (ICAM-
1, VCAM-1), fibrosis (SR) or oxidative stress (3-NT) in the liver was
determined by measuring both stained (Cy3 for Mac-3 and F4/80; 3-
diaminobenzidine for other stainings) and total area of the analysed
image and was subsequently expressed as percentages of stained area
to total analysed area. For each staining, all measurements for each
animal were averaged, and subsequently, data for all animals in one
group were averaged. The presence of bile duct hyperplasia after
drug-induced cholestasis in the periportal region of the acinus in each
liver section was investigated by immunohistochemical detection of
the bile duct epithelial cell antigen CK-19. Two liver sections per
animal were examined for an increased number of CK-19 positive
biliary ductules in each acinus. When the number of CK-19 positive
biliary ductules in each acinus exceeded the number 10, biliary duct
hyperplasia was present. Per section, the frequency of the appearance
of biliary duct hyperplasia was counted and averaged per animal.
Subsequently, data for all animals in one group were averaged.
Gene expression analysis. To monitor gene expression, quantitative
real-time PCR was used. Liver tissue was homogenized with lysing
matrix tubes containing ceramic and silica beads in a Hybaid
Ribolyser (Hybaid Ltd., Thermo, Waltham, MA, USA). Total DNA-
free RNA was extracted with the RNeasy kit (Qiagen, Valencia, CA,
USA), and the concentration was determined spectrophotometrically
(ND-2000, Nanodrop Technologies, Wilmington, DE, USA). To
obtain cDNA, 50 ng of total RNA was incubated with Taqman
Reverse Transcription Kit reagents and random hexamers (Life
Technologies) at 48°C for 60 min. and for 5 min. at 95°C. Taqman
gene expression assays and Taqman Universal PCR Master Mix (Life
Technologies) were used to determine liver mRNA levels with the
ABI-prism Fast 7500 detector (Table 1). PPAR-c1 and PPAR-c2
expression were monitored using primers and probes as described
[16]. b-actin was used as housekeeping gene; its stable expression was
verified throughout the experiments. Data were obtained as cycle
threshold (Ct) values and were normalized to the housekeeping gene
(DCt = Cttarget–Ctb-actin).
Biochemical analysis. Plasma C-reactive protein levels were measured
with a commercially available ELISA (Uscn Life Science Inc.,
Wuhan, China). Levels of the liver enzymes alanine aminotransferase
(ALT), aspartate aminotransferase (AST) and alkaline phosphatases
were analysed using routine laboratory assays. The amount of
triglycerides in the liver was quantified with the triglycerides FS* kit
(Diasys, Holzheim, Germany), after preparation of liver tissue as
described previously [19].
Statistical analysis. Data are presented as means  S.E.M.. Statistical
differences between two groups were determined with the non-
parametric Mann–Whitney U-test. Differences were considered
significant for p < 0.05. The statistical analyses were performed with
GraphPad Prism 4.03 software (GraphPad, La Jolla, CA, USA).
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Results
Effect of genotype. After 4 months on high-fat and high-
cholesterol diet, body-weight of the Akita mice was
significantly lower than that of the wild-type mice kept on the
same diet (19  0.94 g versus 31  1.1 g; p = 0.002). Liver
weight was similar between Akita mice (1.492  71 mg) and
wild-type mice (1.477  64 mg), corresponding to
8.0  0.21% and 4.7  0.12% of total body-weight,
respectively. Food intake was comparable between both groups
(not shown). Elevated levels of plasma alkaline phosphatase and
C-reactive protein were observed in Akita versus wild-type
mice at the start of the diet (Table 2). After 4 months of high-fat
and high-cholesterol diet, untreated Akita mice showed higher
plasma alkaline phosphatase, AST and ALT levels compared
with wild-type controls. Less hepatic lipid accumulation was
noticed in diabetic Akita versus wild-type mice by H&E
staining (fig. 1A,B), which was confirmed by lower triglyceride
levels in hepatic extracts of these mice (8.2  1.7 mg 9 dL1/
mg tissue versus 18  1.9 mg 9 dL1/mg tissue; p < 0.02).
Liver gene expression of the steatosis markers PPAR-a and
PPARc2 was increased in diabetic Akita versus wild-type mice,
while the expression of sterol regulatory element-binding
protein 1c (SREBP1c), PPARc1, cluster of differentiation 36
(CD36) and fatty acid synthase was not influenced by genotype
(Table 3).
Expression analysis in liver tissue of anti-oxidant genes
revealed no effect of genotype of superoxide dismutase 1
(SOD1), catalase (Cat) and glutathione peroxidase 1 (Gpx1)
(Table 3). Of the pro-oxidant genes analysed, only inducible
nitric oxide synthase (iNOS) and endothelial NOS (eNOS)
were down-regulated, whereas xanthine dehydrogenase 1
(Xdh1) and NADPH oxidase-4 (Nox-4) were not significantly
affected. Staining of liver sections for 3-NT, a marker for oxi-
dative stress, indicated no marked effect by genotype
(fig. 1D,E). Quantitative analysis confirmed this finding
(Table 4).
Monitoring of macrophage content in liver tissues by stain-
ing for F4/80 (fig. 1G,H) or Mac-3 (not shown) revealed a
higher Mac-3 expression and a trend towards elevated F4/80
expression in diabetic Akita versus wild-type mice (Table 4).
This was compatible with higher gene expression (lower DCt
values) of the general macrophage markers F4/80, colony-
stimulating factor 1 receptor (Csf1r) and CD68 (Table 3). Rel-
ative gene expression of the M2 macrophage marker arginase
1 (Arg1), but not of mannose receptor 1 (Mrc1), was signifi-
cantly up-regulated in Akita versus wild-type animals. In addi-
tion, the M1 macrophage marker interleukin-6 (IL-6), but not
tumour necrosis factor (TNF)-a or monocyte chemotactic pro-
tein-1 (MCP-1), was significantly up-regulated (Table 3).
The protein expression of cell adhesion molecules ICAM-1
(fig. 1, J and K) and VCAM-1 (fig. 1M,N) was significantly
increased in liver sections of Akita versus wild-type mice
Table 1.
Genes and Taqman gene expression assays.
Abbreviation Name
Taqman gene
expression assay
SREBP1c
or Srebf1
Sterol regulatory
element-binding protein 1c
Mm00550338_m1
PPAR-a Peroxisome proliferator-activated
receptor-a
Mm00440939_m1
CD36 Cluster of differentiation 36 Mm00432403_m1
FAS Fatty acid synthase Mm00433237_m1
Cat Catalase Mm00437992_m1
SOD1 Superoxide dismutase 1 Mm01700393_m1
Gpx1 Glutathione peroxidase 1 Mm00656767_m1
Xdh1 Xanthine dehydrogenase 1 Mm00442110_m1
Nox-4 NADPH oxidase-4 Mm00479246_m1
iNOS Inducible nitric oxide synthase Mm01309902_m1
eNOS Endothelial nitric oxide synthase Mm00435217_m1
Arg1 Arginase 1 Mm00475988_m1
Mrc1 Mannose receptor 1 Mm00485148_m1
TNF-a Tumour necrosis factor-a Mm00443258_m1
IL-6 Interleukin-6 Mm00446190_m1
MCP-1
or Ccl2
Monocyte chemotactic protein-1 Mm00441242_m1
F4/80
or EMR1
EGF-like module-containing
mucin-like hormone
receptor-like 1
Mm00802529_m1
Csf1r Colony-stimulating factor
1 receptor
Mm01266652_m1
CD68 Microsialin Mm03047340_m1
ICAM-1 Intercellular adhesion molecule-1 Mm00516023_m1
VCAM-1 Vascular cell adhesion
molecule-1
Mm01320970_m1
FATP Fatty acid transport protein Mm00449511_m1
MCAD Medium-chain acyl-CoA
dehydrogenase
Mm00431611_m1
Aktb b-actin Mm01205647_g1
Table 2.
Effect of rosiglitazone (RGZ) treatment on liver enzymes of Akita mice.
WT Akita Akita + RGZ
Start 4 months Start 4 months Start 4 months
Alkaline phosphatases (U/l) 227  10 178  29 662  142 343  2123 543  3712 683  7312
CRP (ng/ml) 56  6.9 129  163 83  6.92 165  233 99  112 152  20
AST (U/l) 85  8.1 167  223 111  8.4 382  5723 128  9.72 201  2813
ALT (U/l) 37  5.4 102  243 36  3.3 356  6923 50  10 155  3013
Data are means  S.E.M. of 6 determinations.
1p ≤ 0.05 versus untreated Akita mice.
2p < 0.05 versus wild-type (WT) mice.
3p < 0.05 versus start.
Aspartate aminotransferases (AST), alanine aminotransferases (ALT) and C-reactive protein (CRP).
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(Table 4). Gene expression of ICAM-1 and VCAM-1, how-
ever, was not affected by genotype. With respect to genes
involved in b-oxidation of fatty acids, the mRNA expression
levels of fatty acid transport protein and medium-chain acyl-
CoA dehydrogenase were not affected by genotype (Table 3).
Staining of liver sections with Sirius Red (fig. 1P,Q) did
not indicate marked effects of genotype on collagen deposition
that was located mainly around the blood vessels. Quantitative
analysis confirmed this observation: stained area of
2.1  0.39% for Akita mice versus 2.1  0.096% for wild-
type mice on the same diet (Table 4).
Wild-type and Akita livers were not cholestatic as no hyper-
plasia of the CK-19 positive biliary ductules was found in the
periportal region of the acinus (data not shown).
Effect of treatment. Treatment of Akita mice, kept on high-fat
and high-cholesterol diet for 4 months, with rosiglitazone
A B C
D E F
G H I
J K L
M N O
P Q R
Fig. 1. Rosiglitazone (RGZ) induces steatosis but does not increase oxidative stress, inflammation or collagen deposition in diabetic Akita livers.
Liver tissue of wild-type (WT) and Akita mice kept on a high-fat and high-cholesterol diet for 4 months, without or with addition of rosiglitazone
at a daily dose of 10 mg/kg was immunohistologically analysed using different stainings: (A, B, C) Haematoxylin/eosin staining; (D, E, F) 3-ni-
trotyrosine staining; (G, H, I) F4/80 staining; (J, K, L) intercellular adhesion molecule-1 staining; (M, N, O) vascular cell adhesion molecule-1
staining; (P, Q, R) Sirius Red staining. The scale bars correspond to 20 lm. Magnification: 400 9.
© 2013 Nordic Pharmacological Society. Published by John Wiley & Sons Ltd
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(10 mg/kg per day) resulted in enhanced total body-weight
(24  0.56 g; p < 0.05) as compared to untreated Akita mice.
Liver weight was also enhanced upon rosiglitazone treatment
(2,326  99 mg versus 1,492  71 mg in untreated Akita
mice), corresponding to 9.9  0.54% and 8.0  0.21% of
total body-weight, respectively (p < 0.01). Food intake was
comparable in both groups (not shown). Rosiglitazone
treatment resulted in markedly elevated levels of alkaline
phosphatases and reduced levels of AST and ALT as
compared to untreated Akita mice on the same diet (Table 2).
Rosiglitazone treatment of diabetic Akita mice was associated
with enhanced lipid accumulation in the liver, as shown by
H&E staining (fig. 1B,C). Furthermore, triglyceride levels
were significantly elevated in liver extracts of rosiglitazone-
treated mice (15  1.3 mg 9 dL1/mg tissue versus 8.2 
1.7 mg 9 dL1/mg tissue; p = 0.03) and were comparable
with wild-type mice (18  1.9 mg 9 dL-1/mg tissue). Liver
gene expression of the steatosis markers SREBP1c, PPAR-a,
CD36 and fatty acid synthase was, however, not significantly
affected by rosiglitazone treatment (Table 3).
Expression analysis in liver tissue of anti-oxidant genes
revealed significant down-regulation by rosiglitazone treatment
of SOD1, whereas the expression of Cat and Gpx1 was not
markedly affected (Table 3). Of the pro-oxidant genes analy-
sed, only Xdh1 was down-regulated, whereas Nox-4, iNOS
and eNOS were not significantly affected. Staining of liver tis-
sue sections for the oxidative stress marker 3-NT did not indi-
cate marked effects of rosiglitazone treatment (fig. 1, E and
F). Quantitative analysis confirmed this finding (Table 4).
Monitoring of macrophage content in liver tissues by stain-
ing for F4/80 (fig. 1, H and I) or Mac-3 (not shown) did not
reveal marked effects of rosiglitazone treatment. Stained areas
for rosiglitazone-treated and untreated Akita livers were com-
parable but somewhat enhanced as compared to wild-type
samples (Table 4). This was compatible with unaltered gene
expression of the general macrophage markers F4/80, Csf1r
and CD68 (Table 3). Relative gene expression of the M2 mac-
rophage marker Arg1, but not of Mrc1, was significantly
down-regulated upon rosiglitazone treatment. In addition, the
M1 macrophage marker IL-6, but not TNF-a or MCP-1, was
significantly down-regulated (Table 3).
Staining of liver sections for the cell adhesion molecules
ICAM-1 (fig. 1K,L) and VCAM-1 (fig. 1N,O) did not reveal
significant effects of rosiglitazone. Stained areas of rosiglitaz-
one-treated versus untreated livers were comparable (Table 4).
Gene expression of ICAM-1 was markedly up-regulated by
rosiglitazone treatment of Akita mice, whereas that of VCAM-1
was not affected. With respect to genes involved in b-oxidation
of fatty acids, we observed significantly reduced expression of
fatty acid transport protein in the liver of rosiglitazone-treated
mice as compared to untreated Akita or wild-type mice
(Table 3). Expression of medium-chain acyl-CoA dehydroge-
nase in Akita mice was not affected by treatment. The plasma
level of the acute phase reactant C-reactive protein increased
with the high-fat and high-cholesterol diet in both groups, but
was not affected by rosiglitazone treatment (Table 2).
Staining of liver sections with Sirius Red (fig. 1Q,R) did
not show an effect of rosiglitazone treatment on hepatic colla-
gen content. Quantitative analysis confirmed this observation:
stained area of 1.6  0.19% versus 2.1  0.39% for untreated
Akita mice on the same diet (Table 4).
Table 3.
Effect of rosiglitazone (RGZ) treatment on gene expression in the liver
of Akita mice.
WT Akita Akita + RGZ
Steatosis
SREBP1c 6.2  0.20 5.5  0.23 6.1  0.21
PPAR-a 0.87  0.15 1.7  0.202 1.8  0.232
PPAR-c1 6.7  0.16 6.8  0.15 7.1  0.122
PPAR-c2 8.5  0.36 11  0.442 8.9  0.111
CD36 1.9  0.22 1.2  0.19 1.3  0.0742
FAS 6.3  0.14 6.9  0.32 7.3  0.142
Oxidative stress
Cat 2.4  0.096 1.9  0.33 1.7  0.112
SOD1 0.10  0.10 0.005  0.19 0.56  0.1312
Gpx1 1.7  0.12 1.5  0.20 1.1  0.152
Xdh1 2.6  0.11 2.3  0.17 3.0  0.231
Nox4 5.7  0.14 6.4  0.32 6.5  0.212
iNOS 14  0.33 13  0.392 12  0.262
eNOS 9.2  0.15 8.7  0.182 9.1  0.13
Macrophages
Arg1 0.69  0.13 1.7  0.232 0.10  0.2012
Mrc1 5.6  0.14 5.2  0.27 5.4  0.16
TNF-a 12  0.33 12  0.53 11  0.182
MCP-1 9.9  0.39 9.3  0.51 9.3  0.40
IL-6 15  0.12 14  0.302 16  0.481
F4/80 8.4  0.11 6.9  0.292 6.8  0.142
Csf1r 4.7  0.18 3.9  0.312 4.0  0.122
CD68 13  0.17 13  0.142 13  0.15
Cell adhesion
ICAM-1 6.6  0.25 5.6  0.19 6.9  0.151
VCAM-1 6.6  0.085 5.5  0.39 5.9  0.112
b-oxidation of fatty acids
FATP 5.8  0.23 5.8  0.26 6.8  0.07912
MCAD 0.53  0.16 0.16  0.40 0.22  0.0782
Data are means  S.E.M. of 6 measurements and represent gene
expression values normalized to the housekeeping gene b-actin (DCt
values).
1p < 0.05 versus untreated Akita mice.
2p < 0.05 versus wild-type (WT).
Abbreviations are defined in Table 1.
Table 4.
Quantitation of immunohistochemical analysis of liver sections.
% stained area
WT Akita Akita + RGZ
3-NT 42  3.5 53  1.3 60  3.31
F4/80 6.0  0.73 9.5  2.2 14  4.1
Mac-3 1.2  0.081 2.0  0.291 2.5  0.271
ICAM-1 22  2.4 33  2.01 28  1.4
VCAM-1 4.3  0.86 7.8  1.21 6.6  0.63
Sirius Red 2.1  0.096 2.1  0.39 1.6  0.19
Data are means  S.E.M. of 6 determinations.
1p < 0.05 versus wild-type (WT).
Abbreviations are 3-nitrotyrosine (3-NT), intercellular adhesion mole-
cule 1 (ICAM-1) and vascular cell adhesion molecule 1 (VCAM-1).
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Rosiglitazone treatment did not induce cholestatic liver
injury as no biliary duct hyperplasia was detected in rosiglitaz-
one-treated Akita livers (data not shown).
Discussion
Troglitazone, the first-generation drug of the thiazolidinedione
class to treat type 2 diabetes, was withdrawn from the market
due to several reports of hepatotoxicity. For the second-gener-
ation thiazolidinediones, rosiglitazone and pioglitazone, hepa-
totoxicity was only reported in some patients with enlarged
livers, associated with an increased fat accumulation (hepatos-
teatosis) and occasionally with liver failure [10,11,20–25]. The
mechanism of rosiglitazone-induced liver injury is still unclear
and unpredictable. In general, rosiglitazone has been well tol-
erated in patients with inadequately controlled type 2 diabetes
suffering from non-alcoholic fatty liver disease. In addition,
liver function improved in about 30% of these patients after
treatment [26].
Diabetic Akita mice, kept on a high-fat and high-cholesterol
diet for 4 months, already showed rosiglitazone-induced side
effects such as an increased weight and fat mass gain upon
treatment with 10 mg/kg per day rosiglitazone [16]. In addi-
tion, treatment of these mice with a higher dose of 30 mg/kg
per day rosiglitazone induced left ventricular hypertrophy and
early signs of heart failure [16]. Administration of rosiglitaz-
one at a dose of 10 mg/kg per day to Akita mice was previ-
ously shown to be associated with enhanced plasma
adiponectin levels, decreased glucose levels and increased
insulin sensitivity, confirming the in vivo efficacy of rosiglitaz-
one in this model [16]. In this study, the effect of rosiglitazone
treatment on liver structure and function of diabetic Akita
mice was investigated by determining the stage of non-alco-
holic fatty liver disease ranging from hepatosteatosis (which is
relatively benign) to hepatic inflammation, fibrosis and ulti-
mately progressing to cirrhosis. Rosiglitazone treatment of
Akita mice did not affect liver expression of PPAR-c1,
whereas that of PPAR-c2 was up-regulated to the level of
wild-type mice.
Rosiglitazone treatment induced hepatosteatosis. Histological
analysis of liver sections showed more steatosis in treated as
compared to control Akita mice. This was confirmed by an
elevated triglyceride concentration in liver extracts. Garcia-
Ruiz et al. [27] previously reported significantly enhanced
steatosis and triglyceride content in the liver of ob/ob mice
treated with rosiglitazone. In addition, A-ZIP/F-1 ‘fatless’
mice, in essence lacking white adipose tissue, have a 30%
increased liver triglyceride and fatty acyl-CoA content upon a
3-week rosiglitazone (3 mg/kg per day) administration [28]. A
fatty liver (non-alcoholic hepatosteatosis) is characterized by
elevated circulating levels of ALT and AST, markers of
hepatocellular damage. In this study, however, plasma levels
of the liver enzymes ALT and AST showed a lower trend in
the treated versus the untreated group, suggesting a protective
effect of rosiglitazone against high-fat and high-cholesterol
diet-induced liver damage (as assessed by increased liver ALT
and AST levels after 4 months diet, Table 2). ALP levels
were, however, significantly increased, suggesting induction of
liver injury. Frequently, the ALP test is used to detect
blockage of bile ducts. However, bile duct hyperplasia after
cholestasis liver injury was not detected in liver sections of
rosiglitazone-treated versus untreated Akita animals (data not
shown).
The molecular mechanism of hepatic steatosis in the Akita
mice treated with rosiglitazone may be explained by the
reduced gene expression of fatty acid transport protein. How-
ever, untreated Akita and wild-type mice have a similar liver
fatty acid transport protein gene expression, although there is
clearly less hepatic lipid accumulation in the untreated Akita
versus wild-type mice. A possible explanation for this obser-
vation may be due to the increased energy expenditure seen in
Akita versus wild-type mice [14]. This increased energy con-
sumption has been suggested to result from an enhanced
whole-body lipid oxidation secondary to hypoinsulinaemia as
seen in patients with type 1 diabetes [29]. The relative gene
expression levels of other steatosis markers, such as PPAR-a,
a transcription factor for free fatty acid oxidation [7], and
CD36, a scavenger receptor involved in free fatty acid uptake,
were, however, comparable for the treated and the untreated
mice. In addition, the relative mRNA expression levels of
SREBP1c, a transcription factor involved in de novo lipogene-
sis, and fatty acid synthase, a catalyst for fatty acid synthesis,
were lower in the treated group as compared to the controls,
suggesting that these observed changes in gene expression do
not contribute to the enhanced liver steatosis in rosiglitazone-
treated mice. Gupte et al. [30] in contrast found increased
SREBP1c and fatty acid synthase expression upon rosiglitaz-
one treatment of low-density lipoprotein receptor deficient
mice. In a previous study [31], Otsuka-Long Evans-Tokushi-
ma fatty rats, which develop diabetes, obesity and non-alco-
holic fatty liver disease, were treated with rosiglitazone (4 mg/
kg during 28 weeks). Treatment resulted in mild improvement
of liver steatosis and was associated with enhanced expression
of the fatty acid b-oxidation enzymes fatty acid transport pro-
tein and medium-chain acyl-CoA dehydrogenase.
As oxidative stress or an imbalance between pro- and anti-
oxidant pathways can promote the transition from benign stea-
tosis to steatohepatitis as part of the ‘second hit’ hypothesis of
non-alcoholic steatohepatitis, the gene expression of several
pro- and anti-oxidant markers was examined in the liver of
rosiglitazone-treated and untreated Akita mice. Apparently
conflicting data were obtained. Indeed, whereas the anti-oxi-
dant SOD1 showed a decreased gene expression, suggesting
an increased oxidative stress, the pro-oxidant Xdh1 was also
down-regulated suggesting reduced oxidative stress. Expres-
sion of eNOS, which can be down-regulated by reactive oxy-
gen species (ROS) [32], was not significantly affected by
rosiglitazone treatment, and 3-NT determination further did
not reveal differences in oxidative stress. Although no differ-
ence was found in 3-NT levels, Garcia-Ruiz et al. [27], in
contradiction to our findings, found an increase in oxidative
stress (measured from lipid peroxidation) in the liver of ob/ob
© 2013 Nordic Pharmacological Society. Published by John Wiley & Sons Ltd
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mice treated with 1 mg/kg body-weight per day rosiglitazone.
This increase in liver oxidative stress in rosiglitazone-treated
ob/ob mice may be related to an enhanced mitochondrial func-
tion, which results in the generation of more ROS. Therefore,
it cannot be excluded that the balance between pro- and anti-
oxidant actions favours oxidative stress in the liver of rosiglit-
azone-treated Akita mice, although not detected by 3-NT
staining.
Rosiglitazone treatment did not cause steatohepatitis. In
obese patients with type 2 diabetes, an elevated secretion of
inflammatory cytokines by adipocytes leads to activation of
Kupffer cells (M1 phenotype), hepatocytes and stellate cells.
In hepatocytes, IL-6 can induce the expression of C-reactive
protein. C-reactive protein is an acute phase protein, which
stimulates endothelial cells to produce inflammatory adhesion
molecules, such as ICAM-1 and VCAM-1. In turn, these
components are involved in the transmigration of monocytes
and macrophages to the site of injury [33,34]. In our study,
the plasma level of C-reactive protein, however, was not
different between both groups, in contrast to other animal
and human studies, which reported a reduction of plasma
C-reactive protein [33, 35]. As macrophages and cell
adhesion molecules play an important role in inflammation,
these were further investigated. Rosiglitazone treatment did
not alter gene expression of F4/80, CD68 or csf1r, and the
total liver macrophage content (F4/80- and Mac-3-positive
cells) in treated and untreated mice was similar. An increase
in ROS can switch the polarization of Kupffer cells from an
anti-inflammatory M2 to a pro-inflammatory M1 phenotype;
whereas M2 macrophages act as scavenger molecules and
repair damaged tissues, M1 macrophages produce pro-
inflammatory cytokines and are involved in tissue
destruction [36]. However, in the Akita mice, both the M2
macrophage marker Arg1 and the M1 macrophage marker
IL-6 showed a decreased gene expression in the treated
animals, indicating no enrichment in a specific macrophage
subpopulation. The expression levels of the cell adhesion
molecules, however, suggest a slight decrease in
inflammation after rosiglitazone treatment: ICAM-1 gene
expression was significantly lower and VCAM-1 gene and
ICAM-1 protein expression showed a lower trend in the
treated versus untreated group. As VCAM-1 and ICAM-1
are required for the recruitment of inflammatory cells to
sites of injury, reduced expression may be associated with a
lower inflammatory response.
Rosiglitazone treatment did not cause steatofibrosis. Patients
with type 2 diabetes have a higher risk of developing
steatofibrosis [37]. Liver fibrosis is caused by the
accumulation of extracellular matrix materials, such as
collagen, generated by activated hepatic stellate cells and
myofibroblasts. Activated Kupffer cells, infiltrating
monocytes, activated aggregated platelets and damaged
hepatocytes trigger intracellular signalling cascades that lead
to activation of the stellate cells [38,39]. Histological analysis
of liver sections, however, showed no additional collagen
deposition in the rosiglitazone-treated group. Collagen
deposition was mostly found around the blood vessels, while
in non-alcoholic fatty liver disease patients, fibrosis is found
around the blood vessels and perisinusoidally. Thus, Akita
mice did not show signs of steatofibrosis and rosiglitazone
treatment did not induce this.
In conclusion, in this study, we investigated the effects of
the thiazolidinedione rosiglitazone (10 mg/kg body-weight per
day) on the different stages of non-alcoholic fatty liver disease
in genetically diabetic Akita mice, kept on a high-fat and
high-cholesterol diet for 4 months. An increase in steatosis in
the liver was observed, which may be partially responsible for
the increased liver weight in mice treated with rosiglitazone.
This effect is similar to the steatosis seen in other mouse mod-
els (ob/ob mice and A-ZIP/F-1 fatless mice) and may explain
a potential mechanism in rare cases of rosiglitazone-induced
hepatosteatosis in patients. The progression of steatosis to the
more severe stages of non-alcoholic fatty liver disease, steato-
hepatitis and steatofibrosis (which occurs rarely in rosiglitaz-
one-treated patients) was, however, not observed at the dose
of rosiglitazone tested in the present study. As rosiglitazone
also significantly lowered the plasma level of markers for
hepatocellular damage (AST and ALT) and tended to decrease
liver inflammation, the rosiglitazone-induced liver steatosis in
Akita mice may provide a protection of peripheral tissues such
as muscle and pancreas against the deleterious effects of die-
tary free fatty acid.
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